Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. The company will engage in a fireside chat scheduled for Wednesday, February 12th at 12:00pm ET and conduct virtual one-on-one meetings with investors.
The event will be held virtually, and interested parties can access both the live webcast and archived replay of the fireside chat through the investors section of www.vorbio.com.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -5.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Oppenheimer’s 35th Annual Healthcare Life Sciences Conference.
Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
Fireside Chat: Wednesday, February 12th at 12:00pm ET
Location: Virtual
A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.